Back to Search Results

Marine omega-3 fatty acid supplementation in non-alcoholic fatty liver disease: Plasma proteomics in the randomized WELCOME* trial.

Institute for Life Sciences, University of Southampton, Southampton, UK. Human Development and Health Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK; National Institute for Health Research Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust and University of Southampton, Southampton, UK. Institute for Life Sciences, University of Southampton, Southampton, UK; Tianjin Medical University - School of Pharmacy, Tianjin, China. Institute for Life Sciences, University of Southampton, Southampton, UK; Institute for Cancer Research, London, UK. Institute for Life Sciences, University of Southampton, Southampton, UK; Cancer Sciences Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK; Proteome Exploration Laboratory of the Beckman Institute, California Institute of Technology, Pasadena, CA, 91125, USA. Electronic address: S.D.Garbis@soton.ac.uk.

Clinical nutrition (Edinburgh, Scotland). 2019;(4):1952-1955
Full text from:

Other resources

Abstract

BACKGROUND & AIMS Non-alcoholic fatty liver disease (NAFLD) is a liver condition characterised by liver fat accumulation and often considered to be the liver manifestation of metabolic syndrome. The aim of this study was to examine in patients with NAFLD the system-wide effects of treatment with docosahexaenoic acid + eicosapentaenoic acid (DHA + EPA) versus placebo on the plasma proteome. METHODS Plasma from patients that participated in a 15-18 months randomised, double-blind placebo-controlled trial testing the effects of 4 g DHA + EPA daily was analysed using depletion-free quantitative proteomics. RESULTS Bioinformatics interpretation of the proteomic analysis showed that DHA + EPA treatment affected pathways involving blood coagulation, immune/inflammatory response and cholesterol metabolism (p < 0.05). Two key proteins of cardiovascular risk, prothrombin and apolipoprotein B-100, were shown to decrease as a result of DHA + EPA supplementation [Prothrombin: Males DHA + EPA Mean iTRAQ log2ratio (SD) = -0.13 (0.20) p = 0.05, Females DHA + EPA Mean iTRAQ log2ratio (SD) = -0.48 (0.35) p = 0.03; Apo B-100: Males DHA + EPA Mean iTRAQ log2ratio (SD) = -0.24 (0.16) p = 0.01, Females DHA + EPA Mean iTRAQ log2ratio (SD) = -0.15 (0.05) p = 0.02]. CONCLUSIONS Plasma proteomics applied in a randomised, placebo-controlled trial showed that high dose DHA + EPA treatment in patients with NAFLD affects multiple pathways involved in chronic non-communicable diseases.

Methodological quality

Publication Type : Randomized Controlled Trial

Metadata